Commure vs Biogen
Side-by-side comparison of AI visibility scores, market position, and capabilities
$200M funding 2025; $200M+ ARR (doubled 3 consecutive years); $6B valuation (merged Athelas); 130+ health systems; HCA partnership; acquired Augmedix $139M/Memora; healthcare RCM leader
About
Commure is a healthcare infrastructure company founded to modernize the operational and clinical technology layer of health systems, which have historically relied on fragmented, decades-old software systems for workflows ranging from patient communication to revenue cycle management. The company was co-founded by Tanay Tandon and emerged from General Catalyst's health system subsidiary model, which provides capital and technology directly to large hospital networks. Commure merged with Athelas — an AI-powered revenue cycle management company — in 2023, combining Athelas's proven RCM automation with Commure's broader health system workflow platform to create a more comprehensive enterprise offering.\n\nCommure's platform addresses operational challenges across the health system enterprise including clinical documentation, ambient AI scribing through its Commure Scribe product, revenue cycle automation, patient engagement, and care team communication. The acquisition of Augmedix in 2024 added a leading ambient clinical intelligence capability, enabling physicians to automatically generate clinical notes from patient encounters using AI. Commure serves 130+ health systems and counts HCA Healthcare — one of the largest for-profit hospital networks in the US — as a strategic partner, providing both market validation and scale distribution for its products.\n\nCommure has achieved $200 million+ in annual recurring revenue, doubling for three consecutive years — a growth trajectory that has pushed its valuation to approximately $6 billion. The company's model of embedding deeply within health system operations, rather than selling point solutions that compete at the application layer, creates high switching costs and durable revenue streams. As health systems face intensifying margin pressure and clinician burnout driven by administrative overhead, Commure's AI-driven automation of clinical and operational workflows addresses two of the most urgent priorities simultaneously.
Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.
About
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.